


# Claims

1. A compound of formula (I):




5

wherein:

- $R^1$  represents substituted or unsubstituted heterocyclyl;  
 $Y$  represents  $-(CR_{na}R_{nb})_n-$ ;  
 $R_{na}$  and  $R_{nb}$  are each independently hydrogen or  $C_{1-6}$ alkyl;  
 $n$  is an integer from 1 to 5;  
 $R^2$  represents unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;  
 $R^3$  represents hydrogen or  $C_{1-6}$ alkyl;
- 10 and salts and solvates thereof;  
 with the proviso that the following compound is excluded;  
 N-[[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl]-2-(1,1-dioxidothiomorpholin-4-yl)acetamide.

- 20 2. A compound of formula (I) according to claim 1 wherein  $R^1$  is unsubstituted or substituted pyrandionyl, unsubstituted or substituted uracilyl, unsubstituted or substituted piperidinyl, unsubstituted or substituted hydantoinyl, or unsubstituted or substituted piperazinyl.

- 25 3. A compound of formula (I) according to claim 1 or claim 2 wherein  $R^1$  is pyran-3,4-dion-6-yl, 4-methyluracil-6-yl, 1-(methylcarbonyl)piperidin-4-yl, piperidin-4-yl, 1-(aminocarbonyl)piperidin-4-yl, 1-(cyclopropylaminocarbonyl)piperidin-4-yl, 1-(*tert*-butoxycarbonyl)piperidin-4-yl, 4-(methanesulphonylamino)piperidin-1-yl, 4-(methylcarbonylamino)piperidin-1-yl,  
 30 1-(cyclopropylcarbonyl)piperidin-4-yl, 1-(ethylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylcarbonyl)piperidin-4-yl, 1-(ethoxycarbonyl)piperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, 1-(ethylcarbonyl)piperidin-4-yl, 1-(ethanesulphonyl)piperidin-4-yl, 1-(methylaminocarbonyl)piperidin-4-yl, 1-(methanesulphonyl)piperidin-4-yl, 1-




- 5 4. A compound of formula (I) according to any one of the preceding claims  
wherein R<sub>na</sub> and R<sub>nb</sub> are both hydrogen.
5. A compound of formula (I) according to any one of the preceding claims  
wherein n is 1 or 2.
- 10 6. A compound of formula (I) according to any one of the preceding claims  
wherein R<sup>3</sup> is hydrogen.
7. A compound of formula (I) according to any one of the preceding claims  
15 wherein R<sup>2</sup> is unsubstituted or substituted phenyl or unsubstituted or substituted  
thiophenyl.
8. A compound of formula (I) according to any one of the preceding claims  
wherein R<sup>2</sup> is phenyl substituted with chloro.
- 20 9. A compound of formula (I) according to any one of the preceding claims  
wherein R<sup>2</sup> is 3,4-dichlorophenyl.
10. A compound of formula (I) according to claim 1 selected from the  
25 Examples.
11. A compound of formula (I) according to claim 10 selected from Examples  
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 19, and 20.

12. A compound of formula (I) according to claim 10 selected from Examples 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11.

13. A compound of formula (I) according to claim 10 selected from Examples 1, 2, and 3.

14. A process for the preparation of a compound of formula (I) as defined in claim 1 which process comprises the reaction of a compound of formula (II) with a compound of formula (III);

10




wherein;

15  $R^1$ , Y,  $R^3$ , and  $R^2$  are as hereinbefore defined for formula (I) in claim 1, in the presence of a base and an activating agent and optionally a peptide coupling agent, and thereafter, if required, carrying out one or more of the following optional steps:


- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- 20 (iii) preparing a salt or solvate of the compound so formed.

15. A process for the preparation of a compound of formula (I) as defined in claim 1 wherein Y is  $-CH_2-$  and  $R^1$  is an unsubstituted or substituted N-linked heterocyclyl group i.e. a compound of formula (XI)

25



which process comprises the reaction of a compound of formula (XII) with a compound of formula (XIII);




wherein (XII) is an unsubstituted or substituted heterocyclyl group,  $L^2$  is a leaving group, and  $R^3$  and  $R^2$  are as hereinbefore defined for formula (I) in claim 1, and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.


10

16. A compound of formula (IIIBR)



15 wherein A is a protected amino group and  $R^2$  is as defined for formula (I) in claim 1.


17. A compound of formula (IIIBE)



20

wherein A is a protected amino group and  $R^2$  is as defined for formula (I) in claim 1.

25 18. A compound of formula (XIII)



wherein L<sup>2</sup> is a leaving group and R<sup>2</sup> and R<sup>3</sup> are as defined for formula (I) in claim 1.

5

19. A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

20. A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.

21. Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.

22. A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or rhinitis, which method comprises administering an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.

23. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.

25